Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/23/2025

Inhaled Antibiotics for Non-Cystic Fibrosis Bronchiectasis

Current Approval Status and Evidence

  • The FDA has not approved inhaled tobramycin or colistin for use in non-cystic fibrosis bronchiectasis, despite their clinical use in this population 1
  • Inhaled tobramycin is FDA-approved for cystic fibrosis bronchiectasis in patients 6 years and older with Pseudomonas aeruginosa infection, but not for non-CF bronchiectasis 1
  • The European Respiratory Society guidelines state there is insufficient evidence to recommend routine use of nebulized tobramycin in non-CF bronchiectasis 1, 2
  • Inhaled colistin lacks FDA approval for non-CF bronchiectasis treatment 2

Clinical Evidence for Non-CF Bronchiectasis

  • The British Thoracic Society (BTS) guidelines recommend inhaled colistin for patients with bronchiectasis and chronic Pseudomonas aeruginosa infection (Grade B recommendation) 3
  • Comparative studies show colistin is less effective than tobramycin, with one study showing no improvement in lung function with colistin while tobramycin increased FEV1 by 6.7% 4, 5

Safety Considerations

  • Bronchospasm is a significant concern, reported in multiple studies, with wheezing observed in 50% of patients treated with inhaled tobramycin in one study 2
  • Patients with kidney disease or ear disorders should be treated with caution due to potential systemic absorption 1

Treatment Approach Based on Current Evidence

  • The BTS guidelines suggest using inhaled colistin as first-line therapy for patients with non-CF bronchiectasis and chronic P. aeruginosa infection who have frequent exacerbations 3
  • Inhaled gentamicin can be considered as a second-line alternative for patients with non-CF bronchiectasis and chronic P. aeruginosa infection 3
  • Macrolides (azithromycin or erythromycin) may be used as alternatives if patients cannot tolerate inhaled antibiotics 3

Important Caveats

  • Pre-treatment with bronchodilators is recommended to prevent bronchospasm 1
  • Regular monitoring through sputum cultures is essential to track bacterial density and development of resistance 1

REFERENCES

1

Inhaled Tobramycin Therapy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2007

5

cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2007